Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 1/2 2Phase 1 1

Status

Completed 3

Sponsor Class

NETWORK 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 25Genitourinary 11Thoracic 6Dermatologic 3Gynecologic 2Other hematologic neoplasm 1

Conditions

Melanoma 3Skin Neoplasms 1

Interventions

Dacarbazine 27Nivolumab 26pembrolizumab 22Ipilimumab 203-ingenyl angelate 11Interferon-alpha 10Imiquimod 10Temozolomide 9trametinib 8Vemurafenib 8Photochemotherapy 8Aminolevulinic Acid 8methyl 5-aminolevulinate 7dabrafenib 7cemiplimab 7aldesleukin 7Introns 7Surgical Procedures, Operative 6Radiotherapy 6Interferon alpha-2 6Fluorouracil 6Paclitaxel 5Melphalan 5Interleukin-2 5Cisplatin 5Chemotherapy, Adjuvant 5talimogene laherparepvec 4binimetinib 4Specimen Handling 4Opdualag 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Vinblastine × Dermatologic × Clear all
NCT00003027 2023-06-22

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

Eastern Cooperative Oncology Group

Phase 3 Completed
482 enrolled
Dermatologic

Melanoma

NCT00006237 2015-03-25

S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma

SWOG Cancer Research Network

Phase 3 Completed
432 enrolled 7 charts
Dermatologic

Melanoma

NCT00002882 2011-12-13

Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma

M.D. Anderson Cancer Center

Phase 3 Completed
140 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡